Testing a web application to help patients with acute leukemia
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
This study is testing a new web app to see if it can help people with acute leukemia find and join clinical trials more easily.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06907797 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of the TRIAL web-based application designed to support individuals diagnosed with acute leukemia. The application seeks to reduce barriers to clinical trial enrollment, particularly for underrepresented groups, by providing essential information and resources. Participants will undergo screening for eligibility and complete questionnaires over a participation period of approximately 14 weeks. The study is expected to enroll around 75 participants and is funded by the National Cancer Institute and the American Society of Clinical Oncology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 or older who are English-speaking and have a clinical suspicion of acute leukemia.
Not a fit: Patients who are cognitively impaired or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this application could improve access to clinical trials for patients with acute leukemia, particularly those from underrepresented backgrounds.
How similar studies have performed: While this approach is innovative in its focus on reducing inequity in clinical trial enrollment, similar studies have shown promise in improving access to clinical trials for underserved populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * English speaking * Ability to understand and willingness to sign written informed consent * Clinical suspicion of acute leukemia * Admitted to DFCI-affiliated inpatient unit Exclusion Criteria: * Cognitive impairment rendering the individual unable to participate in beta testing * This will be assessed by focused chart review and consultation with the patients' inpatient care team. * The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners. * Inability to participate in in-person application testing. * Patients who participated in alpha-testing through protocol 23-404 (Appendix A)
Where this trial is running
Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Andrew Hantel, MD — Dana-Farber Cancer Institute
- Study coordinator: Andrew Hantel, MD
- Email: Andrew_hantel@dfci.harvard.edu
- Phone: 617-582-9394
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.